Effective malaria case management requires quick access to diagnostics and antimalarial treatments to reduce illness and death. Artemisinin-based combination therapy (ACT) has been essential to malaria treatment since 2001, as it combines artemisinin for rapid parasite reduction with a partner drug ...to ensure complete cure. However, resistance to antimalarial drugs, where parasites survive standard doses, threatens malaria control.
more
The conditionality of this recommendation is largely driven by the current higher unit cost of pyrethroid-PBO ITNs compared
to pyrethroid-only LLINs and therefore the uncertainty of their cost-effectiveness. Furthermore, as PBO is less wash-resistant
than pyrethroids, its bioavailability declines ...faster over the three-year estimated life of an ITN; therefore, the added impact of
pyrethroid-PBO ITNs over that of pyrethroid-only LLINs may decline over time. The evidence comes from two sites in
eastern Africa with pyrethroid resistance and not from other geographies where transmission levels and vector characteristics
may vary. PBO acts by inhibiting certain metabolic enzymes, primarily oxidases, and so are likely to provide greater protection
than pyrethroid-only LLINs where mosquitoes display mono-oxygenase-based insecticide resistance mechanisms.
more
The MSF malaria guidelines provide practical, evidence-based recommendations for diagnosing, treating, and preventing malaria, especially in low-resource settings. They cover uncomplicated and severe cases, recommend rapid tests and artemisinin-based therapies, and include special guidance for vulne...rable groups like children and pregnant women.
more
Malaria in pregnancy is a significant health problem in malaria-endemic areas. It not only causes substantial childhood morbidity and mortality but also increases the risks of adverse events for pregnant women and their developing fetuses. Most of the burden in these areas is due to infection with P...lasmodium falciparum. Artemisinin-based combination therapy (ACT) has been recommended as first-line treatment for uncomplicated P. falciparum malaria in all populations, including pregnant women in their second and third trimesters, since 2006. However, for women in their first trimester of pregnancy, WHO recommended as first-line treatment a combination of quinine and clindamycin.
Based on a review of the evidence conducted in 2022, WHO now recommends artemether–lumefantrine, the ACT with the most human safety data available, as the preferred treatment for uncomplicated P. falciparum malaria in the first trimester of pregnancy. This document presents all relevant evidence on the effects and safety in early pregnancy of artemisinins and partner medicines used in ACTs from both studies in experimental animals and observational studies in humans.
more
The document outlines essential steps and provides guidance to countries on the adoption and deployment of c-IPTp so that it is integrated into the existing health system. It draws upon best practices and lessons learned from pilot implementation experiences in eight African countries and targets st...akeholders at the national level that are involved in the provision of maternal and child services, including national and local policymakers and implementers of malaria, maternal health, child health, reproductive health and community health programmes, and nongovernmental and other organizations.
more
Le guide décrit les étapes essentielles et donne des orientations aux pays pour l’adoption et le déploiement du c-TPIg de manière à l’intégrer dans le système de santé existant. Il s’appuie sur les meilleures pratiques et les enseignements tirés des expériences pilotes dans 8 pays af...ricains et vise toutes les acteurs impliqués dans la prestation des services pour la mère et l’enfant - responsables politiques nationaux et locaux et acteurs de mise en œuvre des programmes de lutte contre le paludisme, de la santé maternelle, de la santé de l’enfant, de la santé reproductive, des programmes de santé communautaires - ainsi que les organisations non gouvernementales et d’autres organismes. Les pays décidant d’introduire le c-TPIg sont invités à adapter ces orientations à leurs contextes nationaux et locaux.
more
O guia de campo apresenta os passos essenciais e dá orientações aos países sobre a adoção e utilização do c TPIg-c para o integrar no sistema de saúde existente. Baseia-se nas melhores práticas e nas lições aprendidas com as experiências de implementação piloto em oito países african...os, e destina-se às partes interessadas a nível nacional que estão envolvidas na prestação de serviços de saúde materna e infantil, incluindo os decisores políticos a nível nacional e local e os implementadores de programas de paludismo e saúde materna, infantil, reprodutiva e comunitária, assim como organizações não governamentais e outras.
more
The WHO guidelines for malaria bring together the Organization’s most up-to-date recommendations for malaria in one user-friendly and easy-to-navigate online platform.
The WHO guidelines for malaria bring together the Organization’s most up-to-date recommendations for malaria in one user-frie...ndly and easy-to-navigate online platform. The Guidelines supersedes 2 previous WHO publications: the Guidelines for the treatment of malaria, third edition and the Guidelines for malaria vector control. Recommendations on malaria will continue to be reviewed and, where appropriate, updated based on the latest available evidence. Any updated recommendations will always display the date of the most recent revision in the MAGICapp platform. With each update, a new PDF version of the consolidated guidelines will also be available for download on the WHO website.
This version of the Guidelines includes an updated recommendation for malaria vaccines, new recommendations on the use of near-patients qualitative and semiquantitative G6PD tests to guide anti-relapse treatment of P. vivax and P. ovale, updated recommendations on primaquine and the recommendation on the use of tafenoquine. It replaces the versions published on 16 February 2021, 13 July 2021, 18 February 2022, 31 March 2022, 3 June 2022, 25 November 2022, 14 March 2023 and 16 October 2023.
more
Les Lignes directrices de l'OMS sur le paludisme rassemblent les recommandations les plus récentes de l'Organisation pour le paludisme dans une plateforme en ligne facile à utiliser et à naviguer.
Les Lignes directrices de l'OMS sur le paludisme remplacent 2 publications précédentes de l'OMS...: les Lignes directrices pour le traitement du paludisme, troisième édition et les Lignes directrices pour la lutte contre les vecteurs du paludisme. Les recommandations sur le paludisme continueront d'être examinées et, le cas échéant, mises à jour sur la base des dernières données disponibles. Toutes les recommandations mises à jour afficheront toujours la date de la révision la plus récente dans la plateforme MAGICapp. À chaque mise à jour, une nouvelle version PDF des lignes directrices unifiées sera également disponible en téléchargement sur le site Web de l'OMS.
more
Las Directrices de la OMS sobre la malaria reúnen las recomendaciones más actualizadas de la Organización acerca de la malaria (o paludismo) en una plataforma en línea fácil de usar y de navegar.
La primera versión de las Directrices es una recopilación de las recomendaciones existentes de... la OMS sobre la malaria y reemplaza a dos publicaciones anteriores de la OMS: las Directrices para el tratamiento del paludismo, tercera edición (en inglés unicamente), y las Directrices para el control de vectores del paludismo. Se seguirán revisando las recomendaciones sobre la malaria y, cuando proceda, se actualizarán en función de los últimos datos probatorios disponibles. Todas las recomendaciones actualizadas mostrarán siempre la fecha de la revisión más reciente en la plataforma MAGICapp. Con cada actualización, habrá también disponible en el sitio web de la OMS una nueva versión en PDF de las directrices unificadas que se podrá descargar.
Esta versión corresponde a la publicada en inglés el 13 de julio del 2021. La actualización se está traduciendo actualmente.
more
Relapsing malaria caused by Plasmodium vivax parasites poses a significant challenge to global malaria elimination efforts. About one third of the population remains at risk of contracting P. vivax malaria, and 85% of P. vivax infections stem from reactivated latent parasites, leading to chronic ana...emia and increased morbidity and mortality. In addition to diagnostic tools that can detect the acute, blood-stage of P. vivax, new tools are needed to detect the dormant infections before they reactivate and contribute to morbidity and onwards transmission
more
Meeting report, Kampala, Uganda,
7–8 November 2023
BMJ 2024 Mar 13:384:e077512. doi: 10.1136/bmj-2023-077512.
Co-infections in individuals with malaria are common, particularly in endemic areas, and can significantly impact disease severity and outcomes. Effective management requires prompt diagnosis of both malaria and any co-occurring infections,... followed by appropriate treatment strategies
more
Malaria Journal (2024) 23:255. Seasonal malaria chemoprevention (SMC) is a World Health Organization-recommended intervention for the prevention of malaria among children at high risk in areas with seasonal transmission. During the coronavirus disease 2019 (COVID-19) pandemic, SMC drug distribution ...was rapidly adapted to reduce contact and mitigate the risk of transmission between communities and community distributors, with caregivers administering doses.
more
Update, 2023. En 2021, les résultats préliminaires des études d’observation du projet CARAMAL (Community Access to Rectal Artesunate for Malaria) n’ont pas confirmé l’impact sur la mortalité observé dans l’essai contrôlé de 2009. Par conséquent, en janvier 2022, l’OMS a publié un...e note d’information sur l’artésunate rectal, dans laquelle elle suggérait des mesures immédiates d’atténuation des risques.
more
Information note. In 2021, preliminary results of observational studies from the Community Access to Rectal Artesunate for Malaria (CARAMAL) project did not confirm the mortality impact observed in the controlled trial in 2009. Consequently, in January 2022, WHO released an information note on recta...l artesunate (RAS), suggesting immediate risk mitigation measures. To provide clarity on the evidence, WHO subsequently convened independent experts to conduct a formal evidence review of the data from the CARAMAL project, as well as data from other studies evaluating the deployment of pre-referral RAS at programmatic level
more
Actualización de 2023. Nota informativa. En 2021, los resultados preliminares de los estudios observacionales del proyecto de Acceso Comunitario al Artesunato Rectal para el Paludismo (CARAMAL, por sus siglas en inglés) no confirmaron el impacto en la mortalidad observado en el ensayo controlado d...e 2009. En consecuencia, la OMS publicó una nota informativa sobre el artesunato rectal en la que se sugerían medidas inmediatas de reducción del riesgo.
more